LQDA.US Liquidia Technologies Inc

Healthcare Pharmaceuticals USA Stocks
57.41 USD
Close of Nov 15, 2026
22.31 93.61
Market cap
USD 5.17B
P/E
-
P/B
21.96x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LQDA.US undervalued?

Graham number

The Graham number of Liquidia Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Liquidia Technologies Inc fundamental analysis

No fundamental analysis for Liquidia Technologies Inc yet.

Liquidia Technologies Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Liquidia Technologies Inc

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered th…

Full company profile